Cargando...
Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients
Many reference biological therapies have now reached or are near to patent expiry, and therefore a number of biosimilars have been or will be developed. The term biosimilar can be defined as a biotherapeutic product that is similar in efficacy, safety and quality to the licensed reference product. B...
Guardado en:
| Publicado en: | Therap Adv Gastroenterol |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
SAGE Publications
2016
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4830106/ https://ncbi.nlm.nih.gov/pubmed/27134662 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X16636764 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|